EICHOR
● Recruiting
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Condition: Advanced Biliary Tract Cancer · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
About this study
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Zhongshan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06978114